ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2026
Combined use of serum KL-6 and respiratory functional parameters for identifying fibrotic lung damage in SARS-CoV-2-induced interstitial pneumonia.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-COVID19 pulmonary fibrosis (PCPF) has been reported in a significant proportion of patients who survive the acute SARS-CoV-2 infection. Krebs von den Lungen-6 (KL-6) emerges as a marker of disease severity and progression in COVID-19-related lung involvement.
methodsA total of 231 patients (median age (interquartile range, IQR), 65[57-74] years; 143 males) were enrolled in the study. Thirty-four had IPF, 56 sarcoidosis, 141 had been hospitalized for COVID-19. After hospital discharge (median (IQR), 7(5-17) months), a diagnosis of PCPF was made in 65/141 patients and 76/141 did not show fibrotic abnormalities. Serum KL-6 concentrations were measured by KL-6 reagent assay (AIA-CL300, Tosoh Biosciences).
resultsMost PC-nonPF patients (n=70, 92%) did not require invasive mechanical ventilation (IMV) during hospital stay, while 27 (41.5%) of PCPF patients did. KL-6 concentrations were strongly suggestive of lung fibrosis with a cutoff value of 467.8 U/mL (sensitivity 73% and specificity 66%). Model obtained though machine learning approach combined lung parameters and KL-6 values for clustering fibrotic and non-fibrotic patients with an acceptable accuracy. KL-6>765 U/mL and FVC%≤88 cluster for 67% of IPF patients, while KL-6 values ≤765U/mL and FVC >60% for 81% of PCPF patients.
conclusionKL-6 levels are not significantly elevated in patients undergoing IMV, indicating that IMV per se does not alter the values of this biomarker, thereby further supporting its reliability in detecting PCPF. Our study proposed a combination of KL-6 values and clinical data may lead to a further improvement in diagnostic accuracy for pulmonary fibrosis, idiopathic and secondary to COVID19.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.